-
Tom Coates on AI For Pharma Growth: why interim analysis is due an upgrade
Our CEO, Tom Coates, joined Dr Andree Bates on AI For Pharma Growth to talk about interim analysis, why so few trials use it well, and what it would take to catch futility and success years sooner.
-
Publication: Optimal Stoppage of Doomed Processes
Most clinical trials fail, and a failing trial keeps enrolling patients who cannot benefit while costing money.
Yet a substantial share of commercial trials run no interim look at all, and those that do typically check only once, near the halfway point, stopping if the treatment appears futile. -
FIFA World Cup Rule Change Proposal - Leading By 5 Goals Leads to an Automatic Win
Leading by 5 goals is significant. So significant in fact that in the entire 163 year old history of the modern game a 5 goal lead has never been overturned in a top flight game. Maybe time for a rule change?
-
Presentient has received comments from FDA providing clarity on how sponsors can use BRAKES
The FDA comments clarify how the FDA anticipate BRAKES being deployed; sponsors seeking to use BRAKES in the context of a specific clinical trial are to engage with the FDA via individual IND submissions.
-
Presentient Proposes Pilot in Response to FDAs AI-Enabled Optimization of Early-Phase Clinical Trials Pilot Program RFI
-
Whitepaper: BRAKES helps trials stop years earlier
The BRAKES platform accelerates decision-making by months to years while eliminating operational bias.
-
Stay blinded, decide sooner
Want to speed up your clinical trials with early decision making? Want to run 20+ automated interim analyses while eliminating operational bias?